Trials / Active Not Recruiting
Active Not RecruitingNCT06388187
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c.(CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) Once-weekly in Participants With Overweight or Obesity
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cagrilintide | Participants will receive once-weekly cagrilintide subcutaneously. |
| DRUG | Semaglutide | Participants will receive once-weekly semaglutide subcutaneously. |
| DRUG | Placebo | Participants will receive once-weekly placebo matched to cagrilintide and semaglutide subcutaneously. |
Timeline
- Start date
- 2024-06-24
- Primary completion
- 2026-04-21
- Completion
- 2026-04-21
- First posted
- 2024-04-29
- Last updated
- 2026-03-30
Locations
25 sites across 5 countries: United States, Canada, France, Germany, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06388187. Inclusion in this directory is not an endorsement.